Business
Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop and commercialise next-generation products that improve treatment outcomes for people with cancer, is pleased to announce the signing of a commercial-scale Supply Agreement for copper-64 with Nusano.
About this update from Clarity Pharmaceuticals Ltd.
[{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or 64Cu) isotope.","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capacity, which translates into more than 18,000 patient doses per day at 200 MBq per dose, with a 48-hour shelf-life, far in excess of commercial scale demands across multiple large indications.","length":346,"tagName":"p"}]},{"val":[{"type":"text","content":"The copper-64 supply from Nusano will complement Clarity's existing network of US-based suppliers to ensure seamless, abundant production of this diagnostic isotope as the Company is progressing a number of late-stage clinical trials and fast approaching commercialisation.","length":282,"tagName":"p"}]},{"val":[{"type":"text","content":"Nusano plans to begin production of other medical isotopes, such as copper-67 and actinium-225, both of which are used in Clarity's products, in 2025-2026.","length":159,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":927,"olType":false},{"type":"text","content":"SYDNEY, April 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop and commercialise next-generation products that improve treatment outcomes for people with cancer, is pleased to announce the signing of a commercial-scale Supply Agreement for copper-64 with Nusano.","length":395,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Clarity Pharmaceuticals)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Clarity Pharmaceuticals)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":98,"url":"https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fkXRk3krOQ3AG6qYDObpxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7","width":400,"height":98}},"href":"https://mma.prnewswire.com/media/1700068/Clarity_L...